rxc004,panitumumab,bevacizumab,nivolumab,pembrolizumab,denosumab,sotorasib,trifluridine tipiracil
amgen,merck,roche,bms,daiichi sankyo,pfizer,taiho pharma,redx pharma
['solstice', 'lonsurf', 'code,break 101', 'codebreak 101', 'porcupine', 'pembro', 'surf', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)']
 shows: 1) phiii solstice in lonsurf+bev = cape-bev #1l mcrc ineligible for intensive chemo, 2) codebreak 101 soto+folfiri-pmab in pretreated #krasg12c mcrc orr 55% (0 crs), 3) fih phi wnt/porcupine inh cgx1321+pembro 71% sd w/rspo/rnf43 fusion #asco23 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope